RxDoctor Payments Data

Jennelea Montanez, PA

Medical · Omaha, NENPI 1366535049

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 435 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 27.0% of the total. Among medical clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,296in general payments, 2019–2025

Across 435 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$1K
  • Pfizer$468
  • Collegium Pharmaceutical, Inc.$392
  • Scilex Pharmaceuticals Inc.$389
  • Lundbeck LLC$365
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$8,277100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,296 in reported general payments places this provider in the 95th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska

Medicare billing

Part B allowed, 2024
$3,227
Medicare patients
36
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl42$37,472
Buprenorphine94$28,704
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen613$17,066
NucyntaTapentadol Hcl12$15,075
OxycontinOxycodone Hcl35$13,469
Gabapentin539$11,886
Pregabalin285$7,221
Lidocaine19$5,551
Tramadol Hcl371$3,722
Duloxetine Hcl193$3,684
Buprenorphine Hcl59$2,676
Tizanidine Hcl117$2,240
Methocarbamol81$2,046
Celecoxib75$1,968
Cyclobenzaprine Hcl113$1,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta$392$52,54754 claims
Upsher-smith Laboratories LLCTopiramate$51$41543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 medical providers in Nebraska.

Other medical in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →